Interferon-inducible GTPase 5 (GBP5) is being reported in recent immunology/virology work primarily for its antiviral effects—especially how it can interfere with viral protein processing and trafficking in interferon-stimulated cells. For the latest item I can confirm from available sources, a paper published in Nov 2025 reports GBP5 inhibits SARS-CoV-2 spike N-linked glycosylation (via effects on the ER glycosylation machinery), leading to misfolding/ER retention and reduced virion assembly/release.[1]
If you want, tell me whether you mean GBP5 specifically (gene GBP5) and whether you prefer clinical/news, preclinical studies, or drug/biotech developments—and I can narrow the “latest” to that scope. Right now, I can only directly verify the single newest primary finding above from the sources accessible in this session.[1]
Interferon (IFN)-induced guanosine triphosphate hydrolysing enzymes (GTPases) have been identified as cornerstones of IFN-mediated cell-autonomous defence. Upon IFN stimulation, these GTPases are highly expressed in various host cells, where they ...
pmc.ncbi.nlm.nih.govViral infection induces production of type I interferons and expression of interferon-stimulated genes (ISGs) that play key roles in inhibiting viral infection. Here, we show that the ISG guanylate-binding protein 5 (GBP5) inhibits N-linked ...
pmc.ncbi.nlm.nih.govCell-autonomous immunity is essential for host organisms to defend themselves against invasive microbes. In vertebrates, both the adaptive and the innate branches of the immune system operate cell-autonomous defenses as key effector mechanisms that ...
pmc.ncbi.nlm.nih.gov